Krilogy Financial LLC decreased its stake in Merck & Co., Inc. (NYSE:MRK – Get Rating) by 49.7% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 7,699 shares of the company’s stock after selling 7,607 shares during the period. Krilogy Financial LLC’s holdings in Merck & Co., Inc. were worth $702,000 as of its most recent filing with the SEC.
Several other hedge funds have also added to or reduced their stakes in the stock. Landmark Wealth Management LLC bought a new stake in shares of Merck & Co., Inc. in the first quarter valued at approximately $25,000. Joseph P. Lucia & Associates LLC purchased a new position in Merck & Co., Inc. during the first quarter valued at approximately $25,000. Front Row Advisors LLC grew its stake in Merck & Co., Inc. by 89.4% during the fourth quarter. Front Row Advisors LLC now owns 339 shares of the company’s stock valued at $26,000 after acquiring an additional 160 shares in the last quarter. Okabena Investment Services Inc. purchased a new position in Merck & Co., Inc. during the fourth quarter valued at approximately $27,000. Finally, Western Pacific Wealth Management LP purchased a new position in Merck & Co., Inc. during the fourth quarter valued at approximately $29,000. Institutional investors own 73.33% of the company’s stock.
Wall Street Analysts Forecast Growth
MRK has been the subject of several recent analyst reports. Atlantic Securities boosted their price objective on shares of Merck & Co., Inc. from $105.00 to $110.00 and gave the company an “overweight” rating in a research note on Wednesday, July 13th. Mizuho initiated coverage on shares of Merck & Co., Inc. in a research note on Friday, June 24th. They issued a “buy” rating and a $100.00 price target for the company. Morgan Stanley boosted their price target on shares of Merck & Co., Inc. from $88.00 to $92.00 and gave the stock an “equal weight” rating in a research note on Friday, July 29th. Berenberg Bank raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and boosted their price target for the stock from $95.00 to $100.00 in a research note on Wednesday, September 14th. Finally, Daiwa Capital Markets raised shares of Merck & Co., Inc. from a “neutral” rating to a “buy” rating and upped their price objective for the company from $89.00 to $102.00 in a research note on Wednesday, July 6th. Seven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and an average price target of $98.28.
Merck & Co., Inc. Stock Up 3.5 %
Merck & Co., Inc. (NYSE:MRK – Get Rating) last announced its quarterly earnings data on Thursday, July 28th. The company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.67 by $0.20. Merck & Co., Inc. had a net margin of 29.00% and a return on equity of 48.45%. The company had revenue of $14.59 billion for the quarter, compared to the consensus estimate of $13.85 billion. During the same period in the prior year, the firm posted $1.31 EPS. Merck & Co., Inc.’s revenue for the quarter was up 28.0% on a year-over-year basis. As a group, sell-side analysts anticipate that Merck & Co., Inc. will post 7.33 earnings per share for the current fiscal year.
Merck & Co., Inc. Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 7th. Investors of record on Thursday, September 15th will be given a dividend of $0.69 per share. This represents a $2.76 annualized dividend and a yield of 3.15%. The ex-dividend date is Wednesday, September 14th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 42.27%.
Merck & Co., Inc. Company Profile
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.
- Get a free copy of the StockNews.com research report on Merck & Co., Inc. (MRK)
- What Steelcase’s Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.